Skip to main
BCAX

BCAX Earnings Dates & Reports

BCAX Most Recent Earnings

Report Date
Period EndingQ4 2025
Est. EPS-$0.68
Actual EPS-$0.68
EarningsMeet

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

BCAX Earnings per Share (EPS) History

Signup for full access
Browse free

BCAX Latest Earnings

The value each BCAX share was expected to gain vs. the value each share gained.

BCAX reported its most recent earnings on for Q4 2025, posting earnings per share (EPS) of -$0.68. This exceeded analysts' expectations of -$0.68 by 0.00%, marking a Meet.

For comparison, Bicara Therapeutics Inc reported EPS of $0 in the same quarter last year.

The company is expected to announce its next earnings report on , with analysts projecting an EPS of -$0.70.

BCAX Earnings History

Earnings
Est. EPSActual EPSSurprise
Q1 2026
-$0.70
Q4 2025
-$0.68-$0.680.00%
Q3 2025
-$0.54-$0.67+24.07%
Q2 2025
-$0.54-$0.50-7.41%

BCAX Earnings Related Price Changes

Earnings announcements may impact a stock’s price. This table highlights the Bicara Therapeutics Inc’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.

Report datePrice 1D beforePrice 1D afterChange

BCAX Earnings FAQs

BCAX last reported earnings on Mar 30, 2026 for Q4 2025, posting an EPS of -$0.68, which Meet the estimate of -$0.68 by 0.00%.

For Q4 2025, BCAX reported an EPS of -$0.68, missing analysts' estimate of -$0.68 by 0.00%.

For Q4 2025, BCAX Meet expectations with an actual EPS of -$0.68 vs. an estimated EPS of -$0.68.

Following the last earnings report on Mar 30, 2026, BCAX's stock price moved — from — to —.

The next BCAX earnings call is scheduled for May. 12, 2026, where executives will discuss financial results and outlook.

Bicara Therapeutics Inc (BCAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.